GLP-1s are generally well tolerated, with most gastrointestinal side effects subsiding over time
[DOI] [PubMed] [Google Scholar] 118.Delevatti RS, Bracht CG, Lisboa SDC, et al
Understanding this nuanced risk-benefit profile enables informed shared decision-making between healthcare providers and patients considering GLP-1 therapy
Moreover, continued investigation into the pleiotropic effects of GLP-1 receptor agonists may reveal other therapeutic possibilities, possibly transforming the management of many metabolic and non-metabolic disorders
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually strongest when starting or increasing the dose